Claims for Patent: 10,428,059

Summary for Patent: 10,428,059

Title:	Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same
Abstract:	The present invention provides compounds useful for treating or preventing an IL-1R-mediated disease or disorder. In certain embodiments, the disease or disorder comprises scleroderma.
Inventor(s):	Kortagere; Sandhya (Newtown, PA), Artlett; Carol M. (Chesterbrook, PA)
Assignee:	Drexel University (Philadelphia, PA)
Application Number:	15/726,911
Patent Claims:	1. A method of relieving or improving an IL-1R-mediated disease or disorder in a mammal, wherein the IL-1R-mediated disease or disorder is scleroderma or systemic lupus erythematosus (lupus), the method comprising administering to the mammal a therapeutically effective amount of at least one compound, or a salt, tautomer or solvate thereof, wherein the at least one compound is a compound of formula (XI): ##STR00062## wherein in (XI): each occurrence of R.sup.1 is independently selected from the group consisting of H and methyl; R.sup.2 is O or --NH; and R.sup.3 is optionally substituted phenyl or naphthyl. 2. The method of claim 1, wherein the compound is selected from the group consisting of 1,3-dimethyl-5-(naphthalen-1-yl)-5,11-dihydro-1H-indeno[2',1':5,6]pyrido[- 2,3-d]pyrimidine-2,4,6(3H)-trione; and 2-amino-5-(naphthalen-1-yl)-5,11-dihydro-1H-indeno[2',1':5,6]pyrido[2,3-d- ]pyrimidine-4,6-dione; or a salt, tautomer or solvate thereof. 3. The method of claim 1, wherein the mammal is further administered at least one therapeutic agent. 4. The method of claim 3, wherein the therapeutic agent comprises at least one selected from the group consisting of anakinra, rilonacept, azathioprine, methotrexate, bosentan, etanercept, halofuginone, iloprost, cyclophosphamide, cyclosporin A, mycophenolate mofetil, intravenous immunoglobulin, pirfenidone, prednisone, rituximab, beta-glycan peptides, basiliximab, sirolimus, alefacept, terguride, pomalidomide, and a tyrosine kinase inhibitor. 5. The method of claim 3, wherein the compound and the therapeutic agent are co-administered to the mammal. 6. The method of claim 3, wherein the compound is administered to the mammal in a given period of time before or after the therapeutic agent is administered to the mammal. 7. The method of claim 1, wherein the compound is formulated as a pharmaceutical composition. 8. The method of claim 1, wherein the mammal is human.

Details for Patent 10,428,059

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2034-08-04
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2034-08-04
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2034-08-04
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2034-08-04
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2034-08-04
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2034-08-04
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2034-08-04